Cargando…
E7449: A dual inhibitor of PARP1/2 and tankyrase1/2 inhibits growth of DNA repair deficient tumors and antagonizes Wnt signaling
Inhibition of Poly(ADP-ribose) Polymerase1 (PARP1) impairs DNA damage repair, and early generation PARP1/2 inhibitors (olaparib, niraparib, etc.) have demonstrated clinical proof of concept for cancer treatment. Here, we describe the development of the novel PARP inhibitor E7449, a potent PARP1/2 in...
Autores principales: | McGonigle, Sharon, Chen, Zhihong, Wu, Jiayi, Chang, Paul, Kolber-Simonds, Donna, Ackermann, Karen, Twine, Natalie C., Shie, Jue-Lon, Miu, Jingzang Tao, Huang, Kuan-Chun, Moniz, George A., Nomoto, Kenichi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747407/ https://www.ncbi.nlm.nih.gov/pubmed/26513298 |
Ejemplares similares
-
First-in-human study of the PARP/tankyrase inhibitor E7449 in patients with advanced solid tumours and evaluation of a novel drug-response predictor
por: Plummer, Ruth, et al.
Publicado: (2020) -
Neuropilin-1 drives tumor-specific uptake of chlorotoxin
por: McGonigle, Sharon, et al.
Publicado: (2019) -
The telomeric PARP, tankyrases, as targets for cancer therapy
por: Seimiya, H
Publicado: (2006) -
Dissecting the molecular determinants of clinical PARP1 inhibitor selectivity for tankyrase1
por: Ryan, Kevin, et al.
Publicado: (2021) -
Insights into the binding of PARP inhibitors to the catalytic domain of human tankyrase-2
por: Qiu, Wei, et al.
Publicado: (2014)